Immunohistochemical evidence for separate populations of somatostatin-containing and substance P-containing primary afferent neurons in the rat

doi:10.1016/0306-4522(76)90008-7

Neuroscience

Volume 1, Issue 2, April 1976, Pages 131-136, IN19-IN24

https://doi.org/10.1016/0306-4522(76)90008-7 Get rights and content

Abstract

The localization of two small peptides, somatostatin and substance P, has been studied with the indirect immunofluorescence technique. Both peptides were present in small neuronal cell bodies in spinal ganglia, in fibers in the dorsal horn of the spinal cord and in fibers in the intestinal wall. By comparing consecutive sections incubated with antisera to somastostatin and to substance P respectively, it was established that somatostatin, or somatostatin-like immunoreactivity and substance P, or substance P-like immunoreactivity are present in different cells. This is possibly indicated also by a somewhat differential distribution of the immunoreactive fibers in the dorsal horn: the highest concentration of somatostatin-positive fibers was observed in lamina II, whereas abundant substance P-positive fibers were present also in lamina I. Furthermore, numerous substance P-, but no somatostatin-positive fibers, were found around the central canal and in the ventral horns. In the intestinal wall more substance P-positive than somatostatin-positive fibers were seen.

The present results indicate that two subpopulations of primary sensory neurons exist, one containing somatostatin, or somatostatin-like immunoreactivity, and the other containing substance P, or substance P-like immunoreactivity.

References (39)

AlbertiK.G.M. et al.
Inhibition of insulin secretion by somatostatin
Lancet
(1973)
HökfeltT. et al.
Immunohistochemical evidence for the presence of somatostatin a powerful inhibitory peptide, in some primary sensory neurons
Neuroscience Letts
(1975)
HökfeltT. et al.
Experimental immunohistochemical studies on the localization and distribution of substance P in cat primary sensory neurons
Brain Res.
(1975)
KonishiS. et al.
The effects of substance P and other peptides on spinal neurons of the frog
Brain Res.
(1974)
TakahashiT. et al.
Regional distribution of substance P in the spinal cord and nerve roots of the cat and the effect of dorsal root section
Brain Res.
(1975)
TakahashiT. et al.
Identification of the motoneuron-depolarizing peptide in bovine dorsal root as hypothalamic substance P
Brain Res.
(1974)
AndresK.H.
Untersuchungenüber den Feinbau von Spinalganglien
Z. Zellforsch. mikrosk. Anat.
(1961)
ArimuraA. et al.
Radioimmunoassay for GH-release inhibiting factor
BarryJ. et al.
LRF-producing cells of the mammalian hypothalamus
Z. Zellforsch. Microsk. Anat.
(1973)
BrazeauP. et al.
Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone
Science
(1973)

ChangM.M. et al.

Amino acid sequence of substance P

Nature New Biol.

(1971)

ChristensenB.N. et al.

Spinal neurons specifically excited by noxious or thermal stimuli: the marginal zone of the dorsal horn

J. Neurophysiol.

(1970)

ClarkS.L.

Nissl granules of primary afferent neurones

J. comp. Neurol.

(1926)

CoonsA.H.

Fluorescent antibody methods

CurtisD.R. et al.

Amino acid transmitters in the mammalian central nervous system

Rev. Physiol.

(1974)

DahlströmA.

The intraneuronal distribution of noradrenaline and the transport and life-span of amine storage granules in the sympathetic adrenergic neuron

M.D. Thesis

(1966)

DogielA.S.

Der Bau der Spinalganglien des Menschen und der Säugetiere

(1908)

EulerU.S.v. et al.

An unidentified depressor substance in certain tissue extracts

J. Physiol., Lond.

(1931)

HellauerH.

Zur Charakterisierung der Erregungssubstanz sensibler Nerven

Naunyn-Schmiedebergs Arch. exp. Path. Pharmak.

(1953)

Cited by (602)

Effects of methylmercury on spinal cord afferents and efferents—A review
2017, NeuroToxicology
Methylmercury (MeHg) is an environmental neurotoxicant of public health concern. It readily accumulates in exposed humans, primarily in neuronal tissue. Exposure to MeHg, either acutely or chronically, causes severe neuronal dysfunction in the central nervous system and spinal neurons; dysfunction of susceptible neuronal populations results in neurodegeneration, at least in part through Ca²⁺-mediated pathways. Biochemical and morphologic changes in peripheral neurons precede those in central brain regions, despite the fact that MeHg readily crosses the blood-brain barrier. Consequently, it is suggested that unique characteristics of spinal cord afferents and efferents could heighten their susceptibility to MeHg toxicity. Transient receptor potential (TRP) ion channels are a class of Ca²⁺-permeable cation channels that are highly expressed in spinal afferents, among other sensory and visceral organs. These channels can be activated in numerous ways, including directly via chemical irritants or indirectly via Ca²⁺ release from intracellular storage organelles. Early studies demonstrated that MeHg interacts with heterologous TRP channels, though definitive mechanisms of MeHg toxicity on sensory neurons may involve more complex interaction with, and among, differentially-expressed TRP populations. In spinal efferents, glutamate receptors of the N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and possibly kainic acid (KA) classes are thought to play a major role in MeHg-induced neurotoxicity. Specifically, the Ca²⁺-permeable AMPA receptors, which are abundant in motor neurons, have been identified as being involved in MeHg-induced neurotoxicity. In this review, we will describe the mechanisms that could contribute to MeHg-induced spinal cord afferent and efferent neuronal degeneration, including the possible mediators, such as uniquely expressed Ca²⁺-permeable ion channels.
Evidence for a novel, neurohumoral antinociceptive mechanism mediated by peripheral capsaicin-sensitive nociceptors in conscious rats
2017, Neuropeptides
Stimulation of capsaicin-sensitive peripheral sensory nerve terminals induces remote anti-inflammatory effects throughout the body of anesthetized rats and guinea-pigs mediated by somatostatin. As somatostatin has also antinociceptive effects, the study aimed at investigating whether similar remote antinociceptive effects can be demonstrated in awake animals.
In conscious rats, nociceptive nerve endings of the right hind paw decentralized by cutting the sciatic and saphenous nerves 18 h before were chemically stimulated, and drop of the noxious heat threshold (heat hyperalgesia) induced by prior (18 h before) plantar incision was measured on the contralateral, left hind paw using an increasing-temperature water bath. 18 h after nerve transection, mustard oil-evoked plasma extravasation was not significantly reduced in the right hind paw as tested by in vivo fluorescence imaging. Applying agonist of either transient receptor potential vanilloid 1 (TRPV1) or transient receptor potential ankyrin 1 (TRPA1) receptor (capsaicin or mustard oil, respectively) to the nerve-transected paw inhibited the plantar incision-induced drop of the noxious heat threshold on the contralateral paw. The onset of these remote antihyperalgesic effects was 10–20 min. A similar contralateral inhibitory effect of capsaicin or mustard oil treatment was observed on neuropathic mechanical hyperalgesia evoked by partial sciatic nerve injury 2 days before nerve transection and measured by a Randall–Selitto apparatus. The remote thermal antihyperalgesic effect was prevented by chronic (5 days) denervation or local capsaicin desensitization of the stimulated paw; reduced by intraperitoneally applied antagonist of somatostatin (cyclosomatostatin) or opioid receptors (naloxone). The response was mimicked by intraperitoneally applied somatostatin and associated with a 72 ± 27% increase in plasma somatostatin-like immunoreactivity that was absent after chronic (5 days) denervation.
In conclusion, chemical activation of decentralized peripheral capsaicin-sensitive nociceptors evokes remote antihyperalgesic responses initiated outside the central nervous system and mediated by somatostatin and endogenous opioids.
Therapeutic uses of somatostatin and its analogues: Current view and potential applications
2015, Pharmacology and Therapeutics
Citation Excerpt :
However, due to differences in assay sensitivities and species differences, there has been difficulty reaching consensus regarding SSTR expression in immune cells (Pinter et al., 2006). The presence of SST has been demonstrated in nociceptive DRG neurons with C-fibres (Lawson, 1995; Kashiba et al., 1996) and primary afferent neurons (Hokfelt et al., 1976). Here, SST is hypothesised to act on the presynaptic junctions of the sensory-efferent nerve terminals to inhibit the release of transmitters, thereby lending to its anti-inflammatory and anti-nociceptive effects (Green et al., 1992).
Somatostatin is an endogeneous cyclic tetradecapeptide hormone that exerts multiple biological activities via five ubiquitously distributed receptor subtypes. Classified as a broad inhibitory neuropeptide, somatostatin has anti-secretory, anti-proliferative and anti-angiogenic effects. The clinical use of native somatostatin is limited by a very short half-life (1 to 3 min) and the broad spectrum of biological responses. Thus stable, receptor-selective agonists have been developed. The majority of these somatostatin therapeutic agonists bind strongly to two of the five receptor subtypes, although recently an agonist of wider affinity has been introduced. Somatostatin agonists are established in the treatment of acromegaly with recently approved indications in the therapy of neuroendocrine tumours. Potential therapeutic uses for somatostatin analogues include diabetic complications like retinopathy, nephropathy and obesity, due to inhibition of IGF-1, VEGF together with insulin secretion and effects upon the renin–angiotensin–aldosterone system. Wider uses in anti-neoplastic therapy may also be considered and recent studies have further revealed anti-inflammatory and anti-nociceptive effects.
This review provides a comprehensive, current view of the biological functions of somatostatin and potential therapeutic uses, informed by the wide range of pharmacological advances reported since the last published review in 2004 by P. Dasgupta. The pharmacology of somatostatin receptors is explained, the current uses of somatostatin agonists are discussed, and the potential future of therapeutic applications is explored.
Substantia Gelatinosa of the Spinal Cord
2015, The Rat Nervous System: Fourth Edition
The superficial dorsal horn represents the first location in the CNS where the modulation of pain-related information takes place before being forwarded to higher centers. Although it is assumed that changes in the circuitry and excitability of its neurons play a major role in the genesis of pain states, we still know too little about this region of the CNS, even in normal animals. This chapter summarizes the current knowledge regarding the cell populations, chemical neuroanatomy and synaptic circuitry of the three most superficial laminae of the spinal dorsal horn in the rat.
Basic Science of Spinal Receptors
2011, Intrathecal Drug Delivery for Pain and Spasticity
Attenuation of pain-related behavior evoked by injury through blockade of neuropeptide y Y2 receptor
2011, Pain
Neuropeptide Y (NPY) has an important but still insufficiently defined role in pain modulation. We therefore examined the ability of NPY to modulate experimentally induced neuropathic pain by injecting it directly into dorsal root ganglion (DRG) immediately following spinal nerve ligation (SNL) injury. We have found that this application exacerbates pain-related behavior induced by SNL in a modality-specific fashion. When saline was injected after SNL, the expected increase in hyperalgesia responses to needle stimulation was present on the 8th postoperative day. When we injected NPY, hyperalgesic responses were increased in a manner similar to the SNL/saline group. To characterize NPY action, specific Y1 and Y2 antagonists were also delivered directly to DRG, which revealed that behavioral actions of NPY were abolished by Y2 receptor antagonist. We tested whether NPY effects were the result of its role in immunity by immunohistochemical staining for glial fibrillary acidic protein, in order to identify activation of DRG satellite cells and dorsal horn astrocytes. Exacerbation of pain-related behavior following NPY injection was accompanied by astrocyte activation in ipsilateral dorsal horn and with satellite cells activation in the DRG proximal to injury. This activation was reduced following Y2 receptor antagonist application. These findings indicate an important link between pain-related behavior and neuroimmune activation by NPY through its Y2 receptor.

View all citing articles on Scopus

View full text

Immunohistochemical evidence for separate populations of somatostatin-containing and substance P-containing primary afferent neurons in the rat

Abstract

Lancet

Neuroscience Letts

Brain Res.

Brain Res.

Brain Res.

Brain Res.

Untersuchungenüber den Feinbau von Spinalganglien

Z. Zellforsch. mikrosk. Anat.

Radioimmunoassay for GH-release inhibiting factor

LRF-producing cells of the mammalian hypothalamus

Z. Zellforsch. Microsk. Anat.

Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone

Science

Amino acid sequence of substance P

Nature New Biol.

Spinal neurons specifically excited by noxious or thermal stimuli: the marginal zone of the dorsal horn

J. Neurophysiol.

Nissl granules of primary afferent neurones

J. comp. Neurol.

Fluorescent antibody methods

Amino acid transmitters in the mammalian central nervous system

Rev. Physiol.

The intraneuronal distribution of noradrenaline and the transport and life-span of amine storage granules in the sympathetic adrenergic neuron

M.D. Thesis

Der Bau der Spinalganglien des Menschen und der Säugetiere

An unidentified depressor substance in certain tissue extracts

J. Physiol., Lond.

Zur Charakterisierung der Erregungssubstanz sensibler Nerven

Naunyn-Schmiedebergs Arch. exp. Path. Pharmak.